bupropion hydrobromide · Bausch · NDA 022108
Aplenzin
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022108 · 001 · RLD | tablet, extended release, oral | 174MG | open |
| 022108 · 002 · RLD | tablet, extended release, oral | 348MG | open |
| 022108 · 003 · RLD | tablet, extended release, oral | 522MG | open |
Expired or delisted (8)
- US 7241805 · product · 27 Jun 2026
- US 7569610 · use U-997 · 27 Jun 2026
- US 7572935 · product · 27 Jun 2026
- US 7585897 · product · 27 Jun 2026
- US 7645802 · product · 27 Jun 2026
- US 7649019 · product · 27 Jun 2026
- US 7662407 · product · 27 Jun 2026
- US 7671094 · product · 27 Jun 2026